ORA will end its partnership with MercyOne Genesis effective Dec. 18., with ORA no longer providing orthopedic emergency or ...
The Von Willebrand Disease (VWD) market in the United States was valued at over USD 350 million in 2023 and is projected to ...
Emerging therapies for Warm Autoimmune Hemolytic Anemia, including Obexelimab (ZB012), Nipocalimab (M281), and others, are ...